Thus, despite the intimate relationship between PARP and PARG activities, and despite the complexities described above, a differential sensitivity clearly manifests across multiple cell lines, indicating that PARG inhibitors may offer an alternative therapeutic option to target a subset of ovarian cancers, such as HRP tumours that are less likely to respond to PARPi. The gene discussed is PARG; the disease is neoplasm.